HK1051325A1 - New combination of a betablocker and a cholesterol-lowering agent - Google Patents

New combination of a betablocker and a cholesterol-lowering agent

Info

Publication number
HK1051325A1
HK1051325A1 HK03103659A HK03103659A HK1051325A1 HK 1051325 A1 HK1051325 A1 HK 1051325A1 HK 03103659 A HK03103659 A HK 03103659A HK 03103659 A HK03103659 A HK 03103659A HK 1051325 A1 HK1051325 A1 HK 1051325A1
Authority
HK
Hong Kong
Prior art keywords
betablocker
cholesterol
lowering agent
new combination
new
Prior art date
Application number
HK03103659A
Other languages
English (en)
Inventor
Goeran Bondjers
Olov Wiklund
John Wikstrand
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0001188A external-priority patent/SE0001188D0/xx
Priority claimed from SE0002352A external-priority patent/SE0002352D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1051325A1 publication Critical patent/HK1051325A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03103659A 2000-04-03 2003-05-23 New combination of a betablocker and a cholesterol-lowering agent HK1051325A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001188A SE0001188D0 (sv) 2000-04-03 2000-04-03 New combination
SE0002352A SE0002352D0 (sv) 2000-06-22 2000-06-22 New combination
PCT/SE2001/000663 WO2001074394A1 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent

Publications (1)

Publication Number Publication Date
HK1051325A1 true HK1051325A1 (en) 2003-08-01

Family

ID=26655059

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103659A HK1051325A1 (en) 2000-04-03 2003-05-23 New combination of a betablocker and a cholesterol-lowering agent

Country Status (25)

Country Link
US (2) US20030060477A1 (es)
EP (1) EP1272219B1 (es)
JP (1) JP2003528928A (es)
KR (1) KR20020086749A (es)
CN (1) CN1422161A (es)
AR (1) AR030414A1 (es)
AT (1) ATE347909T1 (es)
AU (2) AU2001242985B2 (es)
BR (1) BR0109753A (es)
CA (1) CA2403160A1 (es)
DE (1) DE60125159T2 (es)
EE (1) EE200200570A (es)
ES (1) ES2276774T3 (es)
HK (1) HK1051325A1 (es)
HU (1) HUP0300332A3 (es)
IL (1) IL151589A0 (es)
IS (1) IS6554A (es)
MX (1) MXPA02009705A (es)
MY (1) MY136386A (es)
NO (1) NO20024732L (es)
NZ (1) NZ521351A (es)
PL (1) PL357813A1 (es)
RU (1) RU2002123591A (es)
SK (1) SK14102002A3 (es)
WO (1) WO2001074394A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ITMI20040145A1 (it) * 2004-01-30 2004-04-30 Acraf L-moprololo lpiu' tartrato
MXPA06009054A (es) * 2004-02-11 2007-04-16 Athpharma Ltd Composiciones cronoterapeuticas y metodos de su uso.
CN102091068B (zh) * 2004-05-03 2012-09-19 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物
CN101022791B (zh) * 2004-06-04 2011-11-16 麦兰实验室公司 含奈必洛尔的组合物
CN101534825A (zh) 2006-08-04 2009-09-16 Aska制药株式会社 含有贝特类药物的制剂及其制备方法
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
CN102462844A (zh) * 2010-11-05 2012-05-23 四川滇虹医药开发有限公司 一种替利洛尔的药物组合物及其制备方法
WO2013157833A1 (ko) * 2012-04-18 2013-10-24 서울대학교산학협력단 베타-차단제를 유효성분으로 포함하는 비만, 비만으로 인한 대사성 질환 및 골감소증 예방, 개선 또는 치료용 조성물
CN103613586B (zh) * 2013-11-01 2016-06-08 北京博爱旺康医药科技有限公司 一种旋光纯s-(-)-阿罗洛尔酸式盐及其制备方法和应用
CN103626750B (zh) * 2013-11-15 2016-02-24 北京博爱旺康医药科技有限公司 一种盐酸阿罗洛尔及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
EP0677291A3 (en) * 1991-03-18 1996-08-07 Sepracor Inc Composition and method containing optically pure S-metoprolol.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
NZ512532A (en) * 1998-12-23 2003-12-19 G Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
IL151589A0 (en) 2003-04-10
CA2403160A1 (en) 2001-10-11
AU4298501A (en) 2001-10-15
BR0109753A (pt) 2003-02-04
KR20020086749A (ko) 2002-11-18
PL357813A1 (en) 2004-07-26
RU2002123591A (ru) 2004-03-20
US20040192784A1 (en) 2004-09-30
NO20024732D0 (no) 2002-10-02
AR030414A1 (es) 2003-08-20
NZ521351A (en) 2004-08-27
JP2003528928A (ja) 2003-09-30
IS6554A (is) 2002-09-19
CN1422161A (zh) 2003-06-04
WO2001074394A8 (en) 2002-05-23
DE60125159T2 (de) 2007-10-25
EP1272219B1 (en) 2006-12-13
US20030060477A1 (en) 2003-03-27
MXPA02009705A (es) 2004-02-26
DE60125159D1 (de) 2007-01-25
NO20024732L (no) 2002-10-02
MY136386A (en) 2008-09-30
WO2001074394A1 (en) 2001-10-11
ES2276774T3 (es) 2007-07-01
HUP0300332A2 (hu) 2003-06-28
ATE347909T1 (de) 2007-01-15
SK14102002A3 (sk) 2003-06-03
EE200200570A (et) 2004-04-15
AU2001242985B2 (en) 2005-02-24
EP1272219A1 (en) 2003-01-08
HUP0300332A3 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
AU9272401A (en) Cripto mutant and uses thereof
AU9667901A (en) Mycoattractants and mycopesticides
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
IL155371A0 (en) Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
AU4298501A (en) New combination of a betablocker and a cholesterol-lowering agent
AU2001242985A1 (en) New combination of a betablocker and a cholesterol-lowering agent
GB2377380B (en) Dermatological use and a dermatological preparation
AU8235601A (en) Dispenser and method of use
GB0105613D0 (en) Pharmaceutically effective compounds and their use
HUP0105019A3 (en) Use of cholesterol-lowering agent
GB2365032B (en) A sectional structure and parts thereof
GB0007530D0 (en) Trityl-type compounds and their use
GB0021497D0 (en) Compounds and their use
IL153245A0 (en) New formulation comprising a betablocker and optionally a cholesterol-lowering agent
ZA200207107B (en) New combination of a betablocker and a cholesterol-lowering agent.
AU2001234180A1 (en) Benzamide derivative and use thereof
GB2361272B (en) A set of parts and a coupler assembled therefrom
AU2001239631A1 (en) A new oligomer compound and a use thereof
GB9902590D0 (en) Use of cholesterol-lowering agent
GB0106084D0 (en) Moud and Sa'a
GB2363981B (en) Assemblies of Case-holder and Case
GB0018388D0 (en) Pharmaceutically effective compounds and their use
AU2002224105A1 (en) Piperidine compounds and medicinal use thereof
GB0021927D0 (en) Use of pharmaceutical combination

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110327